血浆凝血酶活化的纤溶抑制物的检测进展
摘要
近年来，凝血酶活化的纤溶抑制物作为纤溶的调节物已成为研究的热点之一。血浆中凝血酶活化的纤溶抑制物水平与纤溶平衡密切相关，是血栓形成的潜在危险因子，因而准确地检测血浆中的凝血酶活化的纤溶抑制物有重要的临床与研究意义，但目前的检测方法较多，优劣各异。现对凝血酶活化的纤溶抑制物检测方法及评价作一综述。
出处
《国际检验医学杂志》
CAS
2007年第2期141-143,共3页
International Journal of Laboratory Medicine
参考文献12
-
1Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor[J]. J Biol Chem, 1998, 273(42): 27176-27181.
-
2Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B [J]. J Biol Chem, 1997, 272(22): 14477-14482.
-
3Schatteman KA, Goossens FJ, Scharpe SS, et al. Proteolytic activation of purified human procarboxypeptidase U[J]. Clin Chim Acta, 2000, 292(1-2): 25-40.
-
4Mosnier LO, von-dem-Borne PA, Meijers JC, et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation [J]. Thromb Haemost, 1998, 80(5): 829-835.
-
5van-Tilburg NH, Rosendaal FR, Bertina RM. Thromhin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis [J]. Blood, 2000, 95(9): 2855-2859.
-
6Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels[J]. Blood, 2001, 98(6): 1992-1993.
-
7Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled [J]. Blood, 2001, 97(7):2053-2058.
-
8Stromqvist M, Schatteman K, Leurs J, et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma [J]. Thromb Haemost, 2001, 85(1): 12-17.
-
9TI: Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma. AU: Willemse JL, Leurs JR, Hendriks DF[J]. J Thromb Haemost, 2005, 3(10): 2353-2355.
-
10Schatteman KA, Goossens FJ, Leurs J, et al. Fast homogeneous assay for plasma procarboxypeptidase U[J]. Clin Chem Lab Med, 2001, 39(9) : 806-810.
-
1江明华（综述）,李向阳（审校）.血浆凝血酶活化的纤溶抑制物的检测进展[J].国际检验医学杂志,2007,28(1):78-80.
-
2杨萍,崔桂萍,王颖,胡静仪.血浆凝血酶激活的纤溶抑制物与脑卒中的相关性[J].天津医药,2009,37(6):469-471. 被引量：1
-
3孟庆义.肌酸激酶同工酶及其亚型的检测进展[J].河北医学,1996,2(6):640-643. 被引量：2
-
4赵树铭,蒋天伦,等.结核分枝杆菌的实验室检测进展[J].中国检验医学与临床,2002,3(3):122-123.
-
5王继德.幽门螺杆菌的核酸杂交和PCR检测进展[J].上海医学检验杂志,1994,9(4):235-237. 被引量：4
-
6张华.PGI2＼TXA2临床检测进展[J].现代医学仪器与应用,1990,2(1):7-9.
-
7周剑涛,吴有才.氧化损伤标志物检测进展[J].临床检验杂志,1995,13(6):335-336. 被引量：2
-
8钟兰君,李晓娜,丁进芳,王凤兰,李芳文,张兴旺.血浆纤溶抑制物与2型糖尿病患者凝血及纤溶功能变化的关系[J].国际检验医学杂志,2006,27(5):401-402. 被引量：2
-
9江明华,吴连拼,陶红群,李向阳,温怀凯.冠心病患者血浆中凝血酶活化的纤溶抑制物测定的意义[J].临床检验杂志,2007,25(6):454-455. 被引量：1
-
10滕峥,张曦.肠道病毒的检测方法及评价[J].上海医学检验杂志,1999,14(4):248-249.
